Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Am J Transplant. 2018 Jan 23;18(7):1699–1709. doi: 10.1111/ajt.14631

Table 1.

Recipient and Donor Characteristics Comparing Female Live Donor Recipients by Donor Relationship

Offspring Donor
n = 1,332
Non-Offspring Donor
n = 1,435
P-value
Recipient Characteristics
 Median age, years (IQR) 59 (53–65) 49 (42–57) <0.001
 African American race, N (%) 369 (28%) 154 (11%) <0.001
 Median dialysis vintage, days (IQR) 322 (0–714) 168 (0–538) <0.001
 Diabetic, N (%) 524 (40%) 378 (27%) <0.001
 Cause of end stage renal disease, N (%) <0.001
  Diabetes 385 (29%) 285 (20%)
  Hypertension 369 (28%) 209 (15%)
  Glomerular disease 184 (14%) 319 (22%)
  Cystic disease 110 (8%) 248 (17%)
  Other cause 195 (15%) 286 (20%)
  Missing 88 (6%) 87 (6%)
 Any pre-transplant sensitization events, N (%) 275 (23%) 324 (25%) 0.286
 Previous kidney transplant, N (%) 58 (4%) 123 (9%) <0.001
 Median body mass index, kg/m2 (IQR) 27.9 (24.2–32.1) 26.7 (22.7–31.6) <0.001
Donor Characteristics
 Median age, years (IQR) 34 (28–40) 46 (38–53) <0.001
 African American race, N (%) 376 (28%) 143 (10%) <0.001
 Male gender, N (%) 527 (40%) 493 (34%) <0.001
 Median cold ischemia time, hours (IQR) 1 (1–2) 1 (1–2) 0.738
 Median body mass index, kg/m2 (IQR) 27.1 (24.3–30.7) 26.2 (23.5–29.5) <0.001
 Median recipient minus donor body mass index (IQR) 0.5 (−3.7–4.9) 0.5 (−4.0–5.0) 0.897
Immunologic Characteristics
 ABO blood type match level 0.631
  Identical, N (%) 1,053 (79%) 1,117 (78%)
  Compatible, N (%) 262 (20%) 302 (21%)
  Incompatible, N (%) 17 (1%) 16 (1%)
 CMV risk status <0.001
  Recipient positive, N (%) 910 (75%) 765 (62%)
  Donor and recipient negative, N (%) 217 (18%) 264 (21%)
  Recipient negative, donor positive, N (%) 85 (7%) 208 (17%)
 Induction immunosuppression 0.799
  Depleting, N (%) 630 (47%) 662 (46%)
  Non-depleting, N (%) 372 (28%) 415 (29%)
  None, N (%) 330 (25%) 358 (25%)
 Calcineurin inhibitor immunosuppression 0.078
  Tacrolimus, N (%) 1,072 (81%) 1,199 (84%)
  Cyclosporine, N (%) 179 (13%) 148 (10%)
  Both, N (%) 3 (0%) 2 (0%)
  Neither, N (%) 78 (6%) 86 (6%)